Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer

  • Reguart N
  • Cardona A
  • Rosell R
  • 10

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

Erlotinib hydrochloride (Tarceva®) is a member of a class of small molecule inhibitors that targets the tyrosine kinase domain of the epidermal growth factor receptor (EGFR), with anti-tumor activity in preclinical models. Erlotinib represents a new-generation of agents known as "targeted therapies" designed to act upon cancer cells by interfering with aberrant specific activated pathways needed for tumor growth, angiogenesis and cell survival. Since its approval in November 2004 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after the failure of at least one prior chemotherapy regimen and with a view to improving patients' outcomes and prevent symptoms, the scientific community has evaluated the potential role of erlotinib in other scenarios such as in maintenance therapy and, in first-line setting for a selected population based on biological markers of response such as mutations of the EGFR. The convenient once-a-day pill administration and the good toxicity profile of erlotinib make it a reasonable candidate for testing in this context. This report provides a review of the role of erlotinib therapy in advanced NSCLC. It summarizes current data and perspectives of erlotinib in upfront treatment and maintenance for advanced NSCLC as well as looking at candidate biomarkers of response to these new targeted-agents. © 2010 Reguart et al.

Author-supplied keywords

  • NCT00446225
  • NCT00874419
  • advanced cancer
  • antineoplastic activity
  • bevacizumab
  • cancer chemotherapy
  • cancer survival
  • carboplatin
  • cetuximab
  • cisplatin
  • clinical trial
  • cytotoxic agent
  • diarrhea
  • docetaxel
  • drug efficacy
  • drug eruption
  • drug safety
  • drug targeting
  • drug tolerability
  • drug withdrawal
  • epidermal growth factor receptor
  • epidermal growth factor receptor 2
  • epidermal growth factor receptor 3
  • epidermal growth factor receptor 4
  • erlotinib
  • gefitinib
  • gemcitabine
  • gene deletion
  • gene mutation
  • human
  • maintenance therapy
  • multiple cycle treatment
  • non small cell lung cancer
  • paclitaxel
  • pemetrexed
  • pharmacogenomics
  • placebo
  • platinum complex
  • primary health care
  • review
  • tarceva
  • unspecified side effect

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • N Reguart

  • A F Cardona

  • R Rosell

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free